In urothelial carcinomas, cervical carcinomas, and oral squamous cell carcinomas, various types of CASZ1 mutations were observed, while in esophageal cancer and prostate cancer, CASZ1 was found to be hypermethylated or silenced by miRNA, respectively, and therefore decreased in expression [71,72,73]. This evidence concerns the gene CASZ1 and prostate cancer.